Zoetis Inc. $ZTS Holdings Lowered by Premier Fund Managers Ltd

Key Points

• Premier Fund Managers cut its Zoetis stake by 96.0% in Q4, selling 60,058 shares and retaining just 2,500 shares worth $316,000.
• Zoetis missed Q1 (EPS $1.53 vs. $1.61 est.; revenue ~$2.26B vs. ~$2.30B) and lowered FY‑2026 guidance to EPS $6.85–7.00 and revenue $9.7–10.0B, triggering a sharp share decline and analyst price-target cuts with a consensus rating of "Hold".
• At the same time, several large institutions materially increased positions — notably Nordea (now ~4.93M shares, ~$622M) and Assenagon (now ~1.63M shares, ~$205M) — leaving institutional ownership at about 92.8%.

Premier Fund Managers Ltd trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 96.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,500 shares of the company's stock after selling 60,058 shares during the quarter. Premier Fund Managers Ltd's holdings in Zoetis were worth $316,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. CIBC Asset Management Inc grew its stake in shares of Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company's stock worth $36,745,000 after purchasing an additional 10,434 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. Seilern Investment Management Ltd grew its stake in shares of Zoetis by 361.2% in the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company's stock worth $41,957,000 after purchasing an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Zoetis by 134.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company's stock worth $205,290,000 after purchasing an additional 935,432 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp grew its stake in shares of Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company's stock worth $43,235,000 after purchasing an additional 18,040 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Livestock and international businesses provided some offset to the U.S. pet weakness, helping limit total company downside and preserving revenue diversification. Quiver Quant: Opinions on Q1
• Positive Sentiment: Some analysts and investors view the sell‑off as an overreaction given Zoetis’s scale, long‑term pet‑humanization trends and its pipeline — creating potential dip‑buy interest from institutions. Quiver Quant: Opinions on Q1
• Neutral Sentiment: Zoetis revised FY‑2026 guidance to EPS $6.85–7.00 and revenue $9.7–10.0B (vs. consensus EPS ~7.03), giving investors updated targets to model into valuations. Zoetis Press Release (PDF)
• Negative Sentiment: Q1 EPS missed expectations ($1.53 vs. $1.61 consensus) and revenue came in light (~$2.26B vs. ~$2.30B est.), triggering the initial sell reaction. Zacks: Q1 miss
• Negative Sentiment: Management cited weaker U.S. companion‑animal demand, price sensitivity among pet owners and lower veterinary visits as the primary drivers of the slowdown — factors that could persist near term and pressure the core domestic business. Benzinga: Weak pet care demand
• Negative Sentiment: Competitive pressure from generics hit legacy products (e.g., Convenia, Cerenia) and strained dermatology/parasiticide growth, raising concerns about near‑term revenue sustainability. Quiver Quant: Competitive pressures
• Negative Sentiment: Market reaction was amplified by heavy trading and negative headlines; coverage and social discussion highlighted the abrupt slowdown and the guidance cut as reasons for a sharp drop in the share price. Fool: Why shares plummeted

Analyst Ratings Changes

Several brokerages have recently issued reports on ZTS. Piper Sandler reaffirmed a "neutral" rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Bank of America lifted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research note on Friday, February 13th. UBS Group dropped their target price on shares of Zoetis from $136.00 to $130.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 28th. Finally, Citigroup began coverage on shares of Zoetis in a research report on Wednesday, April 15th. They issued a "buy" rating and a $145.00 target price on the stock. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $151.75.

Zoetis Stock Performance

Zoetis stock opened at $86.99 on Friday. The firm's 50 day simple moving average is $118.49 and its 200-day simple moving average is $123.70. The company has a market cap of $36.59 billion, a P/E ratio of 14.45, a price-to-earnings-growth ratio of 1.71 and a beta of 0.87. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a fifty-two week low of $85.31 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.26 billion during the quarter, compared to analysts' expectations of $2.30 billion. During the same period last year, the business earned $1.48 earnings per share. The business's revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 7.01 EPS for the current year.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.